Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + cisplatin CCRT followed by PD-1 inhibitor in locally advanced cervical cancer (phase II, single-arm)
ChiCTR2200055686Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and cisplatin in Cervical Cancer (CC), sponsored by Renji Hospital. Primary endpoint: 2-year progression-free survival rate. Started Mar 2022; status: recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2200055686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055686.